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Background: Collecting patient-reported outcome (PRO) data systematically enables objective evaluation of treatment and its
related outcomes. Using disease-specific questionnaires developed by the International Consortium for Health Outcome
Measurement (ICHOM) allows for comparison between physicians, hospitals, and even different countries.
Objective: This pilot project aimed to establish a digital system to measure PROs for new patients with breast cancer who
attended the Charité Breast Center This approach should serve as a blueprint to further expand the PRO measurement to other
disease entities and departments.
Methods: In November 2016, we implemented a Web-based system to collect PRO data at Charité Breast Center using the
ICHOM dataset. All new patients at the Breast Center were enrolled and answered a predefined set of questions using a tablet
computer. Once they started their treatment at Charité, automated emails were sent to the patients at predefined treatment points.
Those emails contained a Web-based link through which they could access and answer questionnaires.
Results: By now, 541 patients have been enrolled and 2470 questionnaires initiated. Overall, 9.4% (51/541) of the patients were
under the age of 40 years, 49.7% (269/541) between 40 and 60 years, 39.6% (214/541) between 60 and 80 years, and 1.3% (7/541)
over the age of 80 years. The average return rate of questionnaires was 67.0%. When asked about the preference regarding paper
versus Web-based questionnaires, 6.0% (8/134) of the patients between 50 and 60 years, 6.0% (9/150) between 60 and 70 years,
and 12.7% (9/71) over the age of 70 years preferred paper versions.
Conclusions: Measuring PRO in patients with breast cancer in an automated electronic version is possible across all age ranges
while simultaneously achieving a high return rate.
(JMIR Cancer 2018;4(2):e11373)   doi:10.2196/11373
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In Germany, every year, 70,000 women receive the diagnosis
of breast cancer. Almost 30% are under the age of 55 years.
Due to improved screening and treatment modalities, there has
been a significant improvement in overall survival in the last
decade [1-3]. Breast cancer-specific mortality in Europe reduced
from 17.90 women in 2002 to 15.20 per 100,000 women in
2012 [4]. However, survival gains are often associated with the
loss of physical functioning; increased morbidity; and new
challenges regarding the emotional, social, and financial aspects
of life [5-8]. Therefore, this increase in life expectancy of
patients with cancer must lead to increased scrutiny regarding
the long-term side effects of new and existing cancer treatments
[9,10]. An important aspect in evaluating effects of any therapies
is patients’ voice and perception. This applies even more to
patients with cancer. The best way to address this aspect is to
use patient-reported outcome (PRO) measures. The US Food
and Drug Agency describes PRO as “any report coming directly
from patients about a health condition and its treatment” [11].
Nowadays, using electronic media, like smartphones and tablet
computers, measuring PRO data is much easier and less time-
and cost-consuming than it was in the past. The use of PRO
data allows for the real-time evaluation of therapy concepts and
monitoring of new treatments. At the same time, it is an easy
way for a long-term follow-up. Increasingly complex therapies
in medicine simultaneously require an increase in
documentation—time missing in direct patient communication
[12,13]. However, this time is essentially needed to adequately
assess a patient’s situation and symptoms. PRO has been shown
in multiple studies to help clinicians to adequately assess patient
symptoms, save time for patient communication, and therefore
improve patient care and even survival [14,15]. The aim of this
study was to establish a PRO system in a major German
university hospital.
Methods
After obtaining ethics approval from the Charité Ethics
Commission (EA 4/127/16), we implemented a Web-based
system to collect PRO data at the Charité Breast Center. Data
capturing started in November 2016. The PRO data collection
was based on an international standard set for breast cancer
outcome measures, which was developed by the International
Consortium for Health Outcome Measurement (ICHOM). All
new patients, who attended the breast clinic, were included in
the PRO measurement. Afterward, those who had a diagnosis
of breast cancer and received their treatment at Charité Breast
Center were stratified into follow-up. After patients registered
at the clinic, they were asked by the receptionist if they would
be willing to participate and received a personal log-in after
they signed consent. The waiting time until their appointment
was used to answer the ICHOM questions as well as questions
regarding their medical history on a tablet computer. The
decision to use a tablet computer in the clinic setting was one
of the comforts because it allowed the patients to continue sitting
where they felt the most comfortable in the waiting area. The
follow-up emails patients received were designed in a way that
they could also be answered on a mobile device.
After the successful completion of the questionnaire, answers
and calculated PRO scores were immediately available to
treating physicians for the upcoming consultation. During that,
treating physicians had the option to add missing clinical data.
If they decide not to record the clinical data necessary, it was
later added by support staff. Once patients entered specific care
pathways, like chemotherapy or surgery, an automated process
was started through which they received follow-up emails
containing the access code to their individual PRO measurement
questionnaires. The follow-up emails were sent 6 weeks after
their first treatment, then every 3 months thereafter for 2 years.
After the first 2 years are finished, they will receive a follow-up
questionnaire every 6 months for another 3 years and after this
only on a yearly basis.
From a technical standpoint, the system for PRO collection was
installed on campus as an on-premise installation. It was
therefore only available within the Charité network. The core
system was supported by an additional patient portal, which
acted as an outward facing tool, to interact with patients. The
patient portal was hosted in a different environment to allow
for access to the Web. It enables patients to complete
questionnaires from home using a secure connection.
Results
Monthly Increase in the Number of Patients Who
Participate in the Patient-Reported Outcome
Measurement Since the Program Implementation
Figure 1 shows monthly increase in the number of patients who
were entered into the PRO evaluation at the Breast Center and
agreed to participate after its implementation in November 2016.
After an initial increase in January 2017 with 40 patients, there
was a decline in participation, with the lowest rate in March
2017, with only 4 patients included. From July 2017, there was
a marked increase in patient numbers—a trend that continued
from there on.
Increase in Patients Numbers for Patient-Reported
Outcome Measurement Compared With the Total
Number of New Patients
Table 1 compares the number of new patients who entered into
the PRO system with the total number of new patients seen at
the Charité Breast Center. With the exemption of January 2017,
where 34.4% (40/116) of the new patients were added to the
PRO system, the percentage of all new patients stayed below
20% until July 2017, with the lowest percentage (4/166, 2.4%)
in March 2017. After July 2017, there was a marked increase
in adding new patients, almost continuously increasing and
reaching its highest percentage in December 2017, with 73.5%
(86/117) of all new patients included in the PRO system.
Table 2 shows patients’ characteristics regarding educational
levels.
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Figure 1. Monthly increase in patient numbers for patient-reported outcome measurement since implementation.
Table 1. Increase in patient numbers for patient-reported outcome measurement over time.















Table 2. Level of academic training in all patients included in patient-reported outcome measurement (N=541).
Value, n (%)Education level
201 (37.1)Minimum German schooling requirement
153 (28.2)Mid-level education
187 (34.5)Higher level education
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Decline in Patient Numbers to Participate in the
Long-Term Follow-Up
Figure 2 shows the percentage of breast cancer patients who
agreed to participate in the electronic follow-up PRO
measurement compared with those who did not want to
participate. In the age group of 20-30 years, 66.67% (2/3) agreed
to follow up; in the age group of 30-40 years, 75% (6/8) agreed
to follow up. The highest number was seen in the age group of
40-50 years, with 90.91% (37/40) followed up; 75.76% (25/33)
agreed to follow up in the age group 60-70 years. Participation
levels were the same, with 75% in the age groups of 70-80
(12/16) and >80 (3/4) years.
Return Rates of Questionnaires From Patients
Participating in the Follow-Up Patient-Reported
Outcome Measurement
Figure 3 shows the return rates of the online questionnaires
completed by those patients who participated in the follow-up
PRO measurement. After an initial drop to 28.6% (12/42) in
February 2017, there was a continuous increase in the return
rate from 54.2% (13/24) in March of 2017 to 82.9% (68/82) in
September 2017, with then another slow decline in October
2017 to 75.3 (70/93). November and December 2017 showed
steady return rates above 81.3% (122/150) and 82.6% (114/138),
respectively.
Preference for Using a Digital Way to Measure
Patient-Reported Outcome Compared With a
Paper-Based Version Across Age Groups
Figure 4 shows the percentage of patients who preferred a
paper-based version of the questionnaire instead of a digital
one. Notably, 100% (51/51) of the patients in the age groups of
20-40 years preferred a digital version, while 2.9% (7/244) of
the patients in the age group of 40-50 years preferred a
paper-based version. This increases to 5.9% (13/122) in the age
group of 50-70 years and then further increases to 13.0% (3/23)
in those aged 70-80 years. Above 80 years of age, there was a
100% (2/2) preference for paper-based questionnaires compared
with digital questionnaires.
Figure 2. Patients who agreed to follow up versus who declined to follow up patient reported outcome measurement.
Figure 3. Return rates of the digital questionnaires completed by patients who participated in the long-term patient-reported outcome measurement.
JMIR Cancer 2018 | vol. 4 | iss. 2 | e11373 | p.4http://cancer.jmir.org/2018/2/e11373/
(page number not for citation purposes)
Karsten et alJMIR CANCER
XSL•FO
RenderX
Figure 4. Preference for paper versus digital questionnaire according to age groups.
Discussion
Principal Findings
This study documents the successful implementation of
measuring PROs using the ICHOM dataset for breast cancer in
a German university hospital for the first time. During the
implementation period, we made numerous observations. First,
it takes at least 6 months to implement and establish a working
system, get all key stakeholders to adopt it, while simultaneously
solve those technical problems that arise during the
implementation phase. Second, most patients, across all age
groups, are willing to participate in the initial measurement as
well as in the long-term follow-up. Third, contrary assumption,
most patients, even those aged >60 years, prefer a digital survey
over a paper-based way to answer the PRO questionnaires.
Our observation regarding the required timeframe to establish
a successful electronic PRO system is matched by previous
publications [16-18]. A crucial point in establishing a successful
digital program is to explain and educate all health care
providers who will be involved in the collection of PROs about
the purpose and benefit of PRO. While there is increasing
interest and knowledge about PRO measurement, there are
concerns regarding workflow, increase in workload due to the
additional measurements, as well as data overload and creation
of additional needs [19-21]. These findings are mirrored in our
low patient accrual data in the first 6 months after the
implementation. It took this time to train, educate, and convince
all involved staff members from front desk staff to treating
physicians. Once this barrier was broken, there was a steady
increase in patients with breast cancer who agreed to participate
in the follow-up PRO measurement. Only a small percentage
of patients declined to participate in the PRO follow-up. The
highest percentage of patients who agreed to follow up was in
the age group of 40-50 years, at an astonishing 90.91% (37/40).
The lowest rate was found in the age group of 20-30 years, with
only 66.67% (2/3) agreeing to follow up. This is in part because
of the low numbers of patients we have in this age group.
Previous work has shown that especially technology literacy
plays a role in the extent to which patients are participating in
electronic-based PRO measurement [22]. We did not gather
information regarding technology literacy but asked a question
regarding the level of education patients had because there have
been data showing a correlation between the level of education
and the willingness to participate in Web-based data collection
as well as the effects regarding PRO-based interventions [15,23].
As shown in Table 2, there was a fairly even distribution of
educational levels in our patient population. Also, the access
and ability to use a computer, smartphone, or smartwatch is a
prerequisite, and therefore, patients who had neither of these
and thereby often did not have an email address were not able
to participate in the study. This could be a potential bias,
especially regarding the return rates.
In addition to the finding that it is possible to establish a
successful PRO measurement program at a German breast center
integrated into the routine clinical workflow, this work showed
for the first time that the majority of patients with breast cancer
treated in a German university hospital preferred a digital survey.
Patients did not want to fill out questionnaires in a paper and
pencil-based version—despite contrary believes. In addition to
this interesting finding, we were able to show that we can
simultaneously achieve a high adherence rate even in the
long-term follow-up. Similar observations have been made
previously in the United States, for example, at Memorial Sloan
Kettering Cancer Center [24], the University of North Carolina
[25], or Group Health Cooperative in Seattle [26].
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Since this is a retrospective analysis of an implementation trial,
it is not without limitations. In the beginning, reasons for decline
in the number of patients participating was not systematically
collected. Since this systematic approach was started only at a
later point, we currently do not have enough data on this matter
but are collecting them now. Also, we did not have enough
resources to be able to contact those patients who decided not
to continue in the follow-up. This point and the first point are
important aspects, and we are currently addressing both and
plan to publish the results in a following publication.
Comparison With Prior Work
While there is an increasing interest in the potential of PRO
measurements in almost all disease entities [27-30], there is still
a lack of standards regarding what to measure and how to
measure it. The ICHOM initiative has therefore created a
working group for a wide range of diseases with the goal to
establish standard sets to compare outcomes between different
providers, hospitals, and even countries [31]. This is the first
published work to show that the implementation of one of their
standard sets—in our case for breast cancer—is feasible and
lays the foundation for further improvements in the complex
care of patients with breast cancer.
Conclusions
The goal of this pilot trial was to create a template on how to
establish a successful Web-based PRO measurement system at
a German university hospital, setting the stage for what to expect
and showing that it is possible to measure PRO in a digital
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